epiglucan and Diabetes-Mellitus

Functional foods have been widely utilized to reduce the symptoms of various diseases such as diabetes mellitus (DM). Among the foods used to combat these effects are soluble fibres, mainly those rich in beta- glucans (BGs).. To review the effects of beta-glucans (BGs) on glucose plasmatic levels of diabetic individuals.. A search was conducted using the Pubmed, Science Direct and Scielo databases using the keywords: diabetes mellitus and beta-glucan and glucose and glycaemia. As inclusion criteria, only studies on diabetic human individuals (type 1 or type 2) who consumed BGs were selected.. Of the 819 initial articles retrieved, only 10 fit the inclusion criteria and were used in the study. It was observed that doses around 6.0g/person/ day, for at least 4 weeks were sufficient to provoke improvements in the blood glucose levels and also lipid parameters of individuals with DM. However, glucose levels do not reach normal levels using BG alone. Low doses of BG for at least 12 weeks were also reported to promote metabolic benefits.. Based on previous research, it was concluded that the ingestion of BGs was efficient in decreasing glucose levels of diabetic patients. The consumption of greater doses or smaller doses for longer periods of time produced better results.. Introducción: Alimentos funcionales han sido ampliamente utilizados para reducir los síntomas de diversas enfermedades como la diabetes mellitus (DM). Entre los alimentos utilizados en el combate de estos efectos, están las fibras solubles, principalmente aquellas que tienen buena cantidad de beta-glucano (BG’s). Objetivo: El objetivo de esta revisión sistemática fue evaluar los efectos de los BG´s en los parámetros metabólicos de individuos diabéticos. Métodos: Fue conducida una búsqueda en las bases de datos Pubmed, ScienceDirect y cielo, utilizando las siguientes palabras-clave: diabetes mellitus and beta- glucano and glucosa and glucemia. Como criterio de inclusión, fueron seleccionados solamente estudios en individuos diabéticos (tipo 1 o tipo 2) que consumieron BG´s. Resultados y Discusión: De los 819 trabajos inicialmente encontrados, 10 artículos se encuadraron en los criterios de inclusión, y por eso fueran utilizados en el estudio. Fue observado que dosis superiores de 6,0 g/ individuo/día, o dosis más grandes que 3,0 g/individuo/ día por un periodo de tiempo más largo, son suficientes para provocar mejoras en los parámetros glucémicos y lipidicos de portadores de DM. Bajas dosis de BG por al menos 12 semanas también presentaron efectos metabólicos benéficos. Conclusión: Tomando en cuenta los resultados observados, se concluye que los BG´s son eficientes en la atenuación de los efectos indeseables del DM, siendo las dosis más grandes o el consumo de pequeñas cantidades por un tiempo más largo las que promueven resultados mejores.

Topics: beta-Glucans; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dietary Fiber; Functional Food; Humans; Hypoglycemic Agents

The objective of this study was to evaluate the scientific evidence on maitake, including expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing. This review serves as a clinical support tool. Electronic searches were conducted in 10 databases, 20 additional journals (not indexed in common databases), and bibliographies from 50 selected secondary references. No restrictions were placed on the language or quality of the publications. All literature collected pertained to efficacy in humans, dosing, precautions, adverse effects, use in pregnancy and lactation, interactions, alteration of laboratory assays, and mechanisms of action. Standardized inclusion and exclusion criteria were used for selection. Grades were assigned using an evidence-based grading rationale. There was a lack of systematic study on the safety and effectiveness of maitake in humans. However, based on popular use and supportive scientific data, three indications are discussed in this review: cancer, diabetes, and immunostimulation. Despite the lack of scientific evidence, maitake mushroom remains a popular agent in commercial products. Future randomized controlled trials are warranted.

Topics: Adjuvants, Immunologic; Animals; beta-Glucans; Diabetes Mellitus; Food-Drug Interactions; Grifola; Humans; Neoplasms

Diabetes mellitus is characterized by high blood glucose level with typical manifestations of thirst, polyuria, polydipsia, and weight loss. It is caused by defects in insulin-mediated signal pathways, resulting in decreased glucose transportation from blood into muscle and fat cells. The major risk is vascular injury leading to heart disease, which is accelerated by increased lipid levels and hypertension. Management of diabetes includes: control of blood glucose level and lipids; and reduction of hypertension. Dietary intake of beta-glucans has been shown to reduce all these risk factors to benefit the treatment of diabetes and associated complications. In addition, beta-glucans also promote wound healing and alleviate ischemic heart injury. However, the mechanisms behind the effect of beta-glucans on diabetes and associated complications need to be further studied using pure beta-glucan.

Topics: beta-Glucans; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Complications; Diabetes Mellitus; Humans; Hypertension; Hypoglycemic Agents; Risk Factors; Treatment Outcome; Wound Healing

Non-cellulosic beta-glucans are now recognized as potent immunological activators, and some are used clinically in China and Japan. These beta-glucans consist of a backbone of glucose residues linked by beta-(1-->3)-glycosidic bonds, often with attached side-chain glucose residues joined by beta-(1-->6) linkages. The frequency of branching varies. The literature suggests beta-glucans are effective in treating diseases like cancer, a range of microbial infections, hypercholesterolaemia, and diabetes. Their mechanisms of action involve them being recognized as non-self molecules, so the immune system is stimulated by their presence. Several receptors have been identified, which include: dectin-1, located on macrophages, which mediates beta-glucan activation of phagocytosis and production of cytokines, a response co-ordinated by the toll-like receptor-2. Activated complement receptors on natural killer cells, neutrophils, and lymphocytes, may also be associated with tumour cytotoxicity. Two other receptors, scavenger and lactosylceramide, bind beta-glucans and mediate a series of signal pathways leading to immunological activation. Structurally different beta-glucans appear to have different affinities toward these receptors and thus generate markedly different host responses. However, the published data are not always easy to interpret as many of the earlier studies used crude beta-glucan preparations with, for the most part, unknown chemical structures. Careful choice of beta-glucan products is essential if their benefits are to be optimized, and a better understanding of how beta-glucans bind to receptors should enable more efficient use of their biological activities.

Topics: Animals; beta-Glucans; Clinical Trials as Topic; Communicable Diseases; Cytokines; Diabetes Mellitus; Fungi; Glucose Metabolism Disorders; Humans; Hypercholesterolemia; Immunologic Factors; Lectins, C-Type; Lymphocytes; Macrophages; Membrane Proteins; Neoplasms; Nerve Tissue Proteins; Phagocytosis; Receptors, Cell Surface; Receptors, Complement; Signal Transduction; T-Lymphocytes, Cytotoxic; Toll-Like Receptor 2

Muesli and cereal based breakfast contain generous amounts of fiber that are helpful in the management of blood glucose levels. Muesli contains β-glucans that ensure gradual rise in blood glucose levels. Muesli also limits the absorption of glucose by making it unavailable. This study explored the effect of muesli in the management of postprandial blood glucose levels. 15 healthy and 15 diabetic females were offered muesli meal after 8h fasting. Fasting blood glucose levels and blood glucose level 30 and 60 minutes after meal were measured. Results of study showed that muesli brought a gradual rise in blood sugar level. Healthy females showed fasting sugar (92.17±11.27), after 30 minutes (110.87±13.85) and after 60 minutes (114.25±15.67) while diabetic females showed fasting sugar (113.25±10.87), after 30 minutes (117.83±18.74) and after 60 minutes (118.26±17.85). The nutritional profile of muesli showed that it contained 202 kcal of energy, 32.7g of carbohydrates, 9g of fiber, 12.4g of protein and 2.5g of fats. It also contained 5.1g of β-glucans. Muesli found to be effective in the management of postprandial blood glucose levels in healthy and diabetic populations.

Topics: beta-Glucans; Blood Glucose; Cross-Over Studies; Diabetes Mellitus; Dietary Carbohydrates; Female; Glucose; Humans; Insulin

The aim of this study was to develop films based on β-glucans in association with pomegranate juice for its potential in metabolic disorders such as diabetes due to plenty of bioactive compounds from the film composition. Initially, a Box-Behnken design was generated by varying the level of β-glucan content (0.5, 1, 1.5 g), sodium alginate (0.2, 0.4, 0.6 g) and pomegranate juice (10, 20, 30 mL) for development of films. Subsequently, glycerin was added as 25% of the total dry matter. The optimization of the films prepared by the solvent casting method was conducted based on the different responses such as: water vapor transmission rate (WVTR), water vapor permeability (WVP), thickness, density, moisture content, solubility, film opacity and color. The water activity profile and FT-IR analysis were performed in all tests. The model was used to determine the optimal experimental values considering that the optimal film will make a sustained contribution to diabetes. The optimal values of the film sample made of β-glucans, sodium alginate, pomegranate juice and glycerin make it befitting for packaging dry powdered pharmaceuticals. Finally, antimicrobial activity against Gram-negative and Gram-positive bacteria, UV barrier properties and microcrack and pore detections through SEM were also investigated for the optimal film sample.

Topics: Alginates; beta-Glucans; Diabetes Mellitus; Glycerol; Pomegranate; Spectroscopy, Fourier Transform Infrared; Steam

Chronic wounds represent a significant health problem worldwide. There is a need for advanced- and cost-efficient wound healing products able to increase patient comfort and reduce the healing time. The aim of this study was to develop a sprayable hydrogel dressing with beta-glucan (βG) as the active ingredient, targeting future application in the treatment of both chronic and burn wounds. The βG was chosen as an active ingredient because of its promising wound healing capabilities, whereas Carbopol 971P NF (Carbopol) was chosen as the thickening agent in the formulation due to several attractive characteristics such as its low viscosity, low toxicity, high transparency and good ion tolerance. Four different hydrogel formulations were prepared with varying Carbopol concentrations. The higher Carbopol concentration, 0.5% (w/w), was used to prepare three formulations comprising the HighCP:NoβG, HighCP:LowβG and the HighCP:MediumβG formulation, respectively. Lower Carbopol concentration, 0.25% (w/w), was used to prepare the LowCP:HighβG formulation. The content of βG varied from 0.25% in the HighCP:LowβG, 0.5% in the HighCP:MediumβG and 1.0% (w/w) in the LowCP:HighβG formulation, respectively. The first part of the study focused on the rheological characterization of the hydrogels and the fluid affinity testing. All formulations were confirmed to be stable gels; the βG was shown to augment the gel strength by increasing the yield strength of the gel in a dose dependent manner. The stability of the formulations containing either Carbopol alone or in a combination with βG did not deteriorate over 26weeks, and the fluid donation and absorption study indicated a fluid donation profile, which favors healing of dry wounds. The in vivo efficacy of the formulations, evaluated in the modified diabetic male mice (db/db mice), showed that Carbopol alone was unable to induce improved healing and caused adverse reactions in some wounds. The inclusion of βG increased the epithelialization and wound contraction in the db/db mice when given at high βG:Carbopol ratio. The positive effect of βG was, however, not sufficient to counteract the adverse effect of Carbopol, thus a more suitable thickening agent should be investigated for further development of a sprayable wound care product.

Topics: Acrylates; Animals; beta-Glucans; Diabetes Mellitus; Disease Models, Animal; Hydrogels; Male; Mice; Rheology; Viscosity; Wound Healing

Baker's yeast glucan (BYG) has been reported to be an anti-diabetic agent. In the work described herein, further study on the effect of orally administered BYG on glucose and lipid homeostasis in the livers of ob/ob mice was performed. It was found that BYG decreased the blood glucose and the hepatic glucose and lipid disorders. Western blotting analysis revealed that BYG up-regulated p-AKT and p-AMPK, and down-regulated p-Acc in the liver. Furthermore, RNA-Seq analysis indicated that BYG down-regulated genes responsible for gluconeogenesis (G6pase and Got1), fatty acid biosynthesis (Acly, Acc, Fas, etc.), glycerolipid synthesis (Gpam and Lipin1/2), and cholesterol synthesis (Hmgcr, Fdps, etc.). Additionally, BYG decreased glucose transporters SGLT1 and GLUT2, fat emulsification, and adipogenic genes/proteins in the intestine to decrease glucose and lipid absorption. All these findings demonstrated that BYG is beneficial for regulating glucose and lipid homeostasis in diabetic mice, and thus has potential applications in anti-diabetic foods or drugs.

Topics: Animals; beta-Glucans; Blood Glucose; Cholesterol; Diabetes Mellitus; Disease Models, Animal; Gluconeogenesis; Glucose; Glucose Transporter Type 2; Humans; Hypoglycemic Agents; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; Saccharomyces cerevisiae; Sodium-Glucose Transporter 1